How the latest prostate cancer research might affect you
08 Mar 2017January 2017 saw the results of the PROMIS trial and the evidence confirmed that the use of a Multi Parametric MRI (mpMRI) scan provides a more accurate diagnosis for men before any biopsy has to be considered.
This is great news for patients as currently in many hospitals the gold standard is to go straight to Trans Rectal ultrasound guided biopsy (TRUS) which are very hit and miss. As a result, in these hospitals many men without cancer undergo unnecessary biopsies, and some men are over diagnosed with prostate cancer which is actually clinically unimportant. Furthermore the study showed that half of all clinically important cancers (those which need treatment to stop the cancer growing) are missed with the TRUS biopsy method.
In addition there are potential side effects, including pain, bleeding and infection.
The results of the trial show that one quarter of men may not need to undergo unnecessary prostate biopsy if they undergo an MRI. MRI also detects 93% of important cancers (compared with 48% for TRUS prostate biopsies).
It is important for patients to know that with the prostate gland, cancer can be detected but it doesn’t always mean radical treatment is necessary. Clinically insignificant cancer can be present but is unlikely to cause any problems during a man’s lifetime.
mpMRI for Prostate Cancer diagnosis in Hampshire
15 Feb 2017
Following the news of the PROMIS trials results and the positive data for mpMRI becoming part of the pathway for Prostate Cancer diagnosis, Hampshire Hospitals are able to offer this diagnostic to NHS patients. Richard Hindley was involved in the trial and patients from Hampshire were part of the study. Urology Partners have used mpMRI for diagnosis for a number of years and are delighted to see it move forward under the NHS.
PROMIS Results Full Report
20 Jan 2017Read the full report of the PROMIS trials which Richard Hindley.. was part of and bought in 160 patients from Hampshire and Surrey through North Hampshire Hospital
Genetic test tells patient if prostate cancer is likely to spread
10 Jan 2017
New research has discovered a genetic link to whether localised prostate cancer will advance and spread. If developed, this could allow far more personalised and specific treatment for patients with prostate cancer and knowing how they might respond to treatment.